Compare · AIKI vs SBTX

AIKI vs SBTX

Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Silverback Therapeutics Inc. (SBTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AIKI and SBTX operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
  • SBTX has more recent analyst coverage (6 ratings vs 1 for AIKI).
MetricAIKISBTX
Company
AIkido Pharma Inc.
Silverback Therapeutics Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Specialty Chemicals
Specialty Chemicals
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
0
0
Recent ratings
1
6
AIKI

AIkido Pharma Inc.

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.

SBTX

Silverback Therapeutics Inc.

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Latest AIKI

Latest SBTX